Research programme: antibacterials - Hsiri TherapeuticsAlternative Names: HT-06; HT-07; HT-10
Latest Information Update: 02 Sep 2016
At a glance
- Originator University of Notre Dame
- Developer Hsiri Therapeutics
- Class Antibacterials
- Mechanism of Action Bacterial growth inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Bacterial infections